Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Urol
Main Authors: Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2014
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236626/
https://ncbi.nlm.nih.gov/pubmed/24458878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1244-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki